Purpose: To implement the best available evidence for the dermal assessment and management of insulin injection sites in pediatric diabetes patients and to evaluate the application's effectiveness. Methods: Guided by the Evidence-Based Continuous Quality Improvement Model, following a systematic literature screening and quality assessment process, 12 publications were included (7 guidelines, 2 expert consensuses, 1 systematic review , 1 evidence summary , and 1 metaanalysis).From these, 24 best evidence recommendations were extracted across six key dimensions: pre-assessment preparation, assessment frequency , assessment content and methods, injection technique, injection site selection, and post-assessment management. The aggregated best evidence was translated into 24 audit criteria. A baseline audit was conducted, and facilitators and barriers were analyzed via SWOT analysis to guide practice changes. We compared the compliance rates with the audit criteria and the incidence of injection site complications (including subcutaneous fat hyperplasia, lipoatrophy , pain, bleeding, and bruising) before and after the evidence-based intervention. The chi-square test was employed for statistical analysis. Results: Following the intervention, nursing staff's compliance with the evidence-based audit criteria significantly improved compared to the baseline level. The incidence of all documented complications—subcutaneous fat hyperplasia, lipoatrophy , pain, bleeding, and bruising—was significantly reduced. A statistically significant difference was specifically noted for 'bruising' (χ² = 4.444, P = 0.035). Conclusion: The application of best evidence for the dermal care of insulin injection sites in pediatric diabetes is effective in enhancing nursing guideline adherence, reducing the incidence of cutaneous complications, and improving overall disease management in children.